SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is experiencing intense downward pressure, hitting new multi-year lows as investors weigh concerns over China market demand, tariff impacts, and increased competition against a leadership-led turnaround effort. While the community remains dividedwith some viewing the current price as a generational value opportunity and others bracing for further downside toward the $40 levelactive discussions are centered on whether the upcoming earnings report will confirm a stabilization in margins or trigger further selling.

RH operates as a holding company which operates the business through its subsidiary Restoration Hardware, Inc. It offers furniture, lighting, textiles, bath ware, decor, outdoor and garden, as well as baby and child products. The company operates an integrated business with multiple channels of distribution including galleries, source books and websites. The company was founded by Stephen J. Gordon in 1980 and is headquartered in Corte Madera, CA.

RH - Ordinary Shares - Class A

Restoration Hardware

Restoration Hardware (RH) is experiencing heightened volatility and intense community debate as investors weigh the company's recent earnings results, persistent tariff risks, and ongoing concerns regarding the luxury housing market. While some market participants are aggressively positioning for a potential short squeeze or recovery driven by leadership changes and long-term expansion plans, others remain skeptical, citing high debt levels and poor consumer demand for high-end furniture.

BRC Group Holdings, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.

BRC Group Holdings Inc.

B. Riley Financial Inc

B. Riley Financial is trending as the community closely monitors the upcoming 10-K filing and earnings report, with sentiment buoyed by aggressive debt reduction and the stellar performance of major holdings like BW and APLD. Investors are actively discussing the potential for a significant valuation re-rating and short squeeze, viewing the recent clearing of share pledges by the CEO as a major catalyst that could force bearish positions to unwind.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors digest the commercial launch of Yartemlea following recent FDA approval, with the community actively debating the company's long-term value, revenue potential, and the impact of the partnership with Novo Nordisk. Despite volatility from short interest and options-related pressure, discussions remain focused on upcoming catalysts such as EMA regulatory decisions and the broader outlook for the company's pipeline.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing intense community debate as investors weigh the company's transition from R&D to production-scale manufacturing, with recent chatter heavily focused on interpreting potential indirect ties to major industry players like NVIDIA and Marvell. While bulls emphasize the strategic long-term value of their optical interposer technology and validated partnerships, bears remain vocal about the lack of significant near-term revenue and the ongoing dilution risk that has fueled skepticism regarding management's execution.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is generating significant community interest driven by its role as a high-speed, low-cost settlement rail, with many participants viewing it as a top-tier asset alongside Bitcoin and Ethereum for institutional adoption. The conversation remains highly active, split between bullish narratives around its ecosystem scalability and traders focusing on opportunistic entries amid ongoing market volatility.

Dave & Buster's Entertainment, Inc. engages in the ownership and operation of entertainment and dining venues under the name Dave & Buster's. It offers a full menu of entrées and appetizers, a selection of alcoholic and non-alcoholic beverages, and an assortment of entertainment attractions centered around playing games and watching live sports and other televised events. The company was founded by David O. Corriveau and James W. Corley in 1982 and is headquartered in Coppell, TX.

Dave & Buster`s Entertainment Inc

Dave & Buster's Entertainment

Dave & Buster's is currently a focal point for investors due to its high short interest and speculative potential for a short squeeze, despite ongoing concerns about its business model and the impact of discretionary spending shifts. The community is actively debating the company's turnaround strategy under new leadership while weighing the risks of its significant debt levels against the possibility of institutional share accumulation.

"What's Updog?" is a Community Led token.

UpDog

UpDog is generating significant buzz as community members rally to drive momentum and advocate for broader retail participation in the memecoin space. Discussions are centered on the token's long-standing presence in the market, with participants actively sharing swap details and engaging in playful, meme-driven social activity.

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

ORIC Pharmaceuticals Inc

ORIC Pharmaceuticals is trending following positive preliminary efficacy and safety data from its Phase 1b trial of ORIC-944 in combination with androgen receptor inhibitors for prostate cancer. Investors are actively discussing the significance of the company's recent capital raise, its partnership with Pfizer, and the potential for a short squeeze given the high short interest.

nCino, Inc. engages in the provision of cloud-based software applications for financial institutions in the United States and internationally. Its nCino Bank Operating System, a tenant cloud platform, digitizes, automates, and streamlines complex processes and workflow, and utilizes data analytics and artificial intelligence and machine learning (AI/ML) to enable financial institutions to onboard new clients, make loans, and manage the entire loan life cycle, open deposit and other accounts, and manage regulatory compliance. The firm's nCino IQ is an application suite that utilizes data analytics and AI/ML to provide its customers with automation and insights into their operations, such as tools for analyzing, measuring, and managing credit risk, as well as to enhance their ability to comply with regulatory requirements. The company was founded by Pierre Naudé in 2011 and is headquartered in Wilmington, NC.

Ncino Inc.

nCino is seeing significant market activity driven by the announcement of a $100 million accelerated share repurchase program and a strong earnings report that topped expectations. The community is actively discussing the stock's growth potential and ongoing share buyback strategy while reacting to the company's fiscal outlook.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Short Interest in CapsoVision, Inc. (NASDAQ:CV) Grows By 35.2%

CapsoVision, Inc. (NASDAQ:CV - Get Free Report) was the recipient of a large increase in short interest in the month of March. As of March 13th, there was short interest totaling 553,348 shares, an...

CapsoVision (NASDAQ:CV) Price Target Lowered to $10.00 at Benchmark

Benchmark lowered their target price on shares of CapsoVision from $14.00 to $10.00 and set a "speculative buy" rating on the stock in a research note on Friday...

CapsoVision Q4 Earnings Call Highlights

CapsoVision (NASDAQ:CV) executives highlighted continued commercial growth for its CapsoCam Plus small-bowel capsule endoscopy product and provided updates on regulatory and clinical milestones for...

CapsoVision Q4 25 Earnings Conference Call At 4:30 PM ET

(RTTNews) - CapsoVision, Inc (CV) will host a conference call at 4:30 PM ET on March 26, 2026, to discuss Q4 25 earnings results...

CapsoVision Conference: CEO Maps AI-Driven Capsule Endoscopy Roadmap for Colon and Pancreas Screening

CapsoVision (NASDAQ:CV) executives used a fireside chat hosted by Roth Senior Research Analyst Kyle Bauser to outline the company's origins, its capsule endoscopy platform for small bowel visualization, and development plans for future GI indications including colon and pancreas. Management also dis...

CapsoVision, Inc. (NASDAQ:CV) Short Interest Update

CapsoVision, Inc. (NASDAQ:CV - Get Free Report) was the recipient of a significant growth in short interest in the month of February. As of February 13th, there was short interest totaling 429,030...

Short Interest in CapsoVision, Inc. (NASDAQ:CV) Increases By 281.0%

CapsoVision, Inc. (NASDAQ:CV - Get Free Report) saw a significant growth in short interest in January. As of January 30th, there was short interest totaling 357,735 shares, a growth of 281.0% from...

Short Interest in CapsoVision, Inc. (NASDAQ:CV) Declines By 57.4%

CapsoVision, Inc. (NASDAQ:CV - Get Free Report) was the target of a large decline in short interest during the month of January. As of January 15th, there was short interest totaling 93,892 shares, a...

CapsoVision Submits FDA 510(k) for AI-Assisted Module in CapsoCam Plus

CV seeks FDA clearance to add AI-based reading to CapsoCam Plus to boost diagnostic accuracy and streamline reviews.

CapsoVision (NASDAQ:CV) Shares Gap Down - Here's Why

CapsoVision (NASDAQ:CV) Shares Gap Down - Here's What Happened...

CapsoVision, Inc. operates as a commercial-stage medical technology company. It engages in the development of imaging and artificial intelligence (AI) technologies that are deployed for endoscopy solutions to identify abnormalities of the gastrointestinal (GI) tract for diagnostic and screening purposes. The firm developed capsule endoscope system, currently comprising the CapsoCam Plus single-use capsule and the CapsoCloud and CapsoView software, to panoramically visualize the small-bowel mucosa to investigate abnormalities such as obscure GI bleeding and Crohn’s disease. The company was founded by Kang-Huai Wang on August 1, 2005 and is headquartered in Saratoga, CA.

CapsoVision Inc.

iShares Dynamic Equity Active ETF ($BDYN)

Grayscale Bitcoin Trust ETF ($GBTC)

Destiny Tech100 Inc ($DXYZ)

Global X Defense Tech ETF ($SHLD)

The Modern Portfolio Builder. This award honors the fund that makes long-term investing easier, cheaper, or more effective for people who want to "set it and forget it."

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.13	--	--	N/A
Q4 '25	-$0.14	--	--	N/A
Q3 '25	-$0.12	-$0.17	-37.15%	MISSED
Q2 '25	-$0.11	-$2.02	-1736.36%	MISSED

CV
Central Vermont Public Service Corp.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q1 '26

Historical Earnings

Latest CV News

CVCentral Vermont Public Service Corp.